文献速递瓣膜外科先天性心脏病外科

儿童二尖瓣置换术后生存与再干预的预测因素

Predictors of survival in paediatric mitral valve replacement.
PubMed 文献 · Eur J Cardiothorac Surg · 2021-01-01

该单中心回顾性研究纳入1982至2019年间115例18岁以下接受二尖瓣置换的患儿,计算瓣膜尺寸(mm)与体重(kg)比值并评估远期结果。结果显示5年与10年无死亡或移植生存率分别为77±4%与72±5%,尺寸/体重比值>2和年龄<2岁为死亡或移植的显著危险因素。

要点

  • 尺寸/体重比值>2和年龄<2岁与死亡或移植风险升高相关
  • 首次置换使用生物瓣及尺寸/体重比值>2为再手术预测因素
  • 再置换时可行且常可置入更大尺寸的二尖瓣假体

核心结论

  • 二尖瓣置换是儿童不可修复二尖瓣疾病的可行策略。
  • 死亡风险可基于尺寸/体重比值和年龄<2岁预测。
  • 二尖瓣再置换的并发症和死亡率低,再手术时常可置入更大尺寸假体。

研究设计与样本

  • 单中心回顾性研究,纳入1982至2019年间115例18岁以下接受二尖瓣置换的患者。
  • 计算所有患者手术时人工瓣膜尺寸(直径mm)与体重(kg)的比值并评估远期结果。
  • 主要结局为无二尖瓣再置换,复合次要结局为无死亡或移植。

主要发现

  • 手术时中位年龄5.5岁(四分位距1.21-9.87)。
  • 5年无死亡或移植生存率为77±4%,10年为72±5%。
  • 单因素分析显示尺寸/体重比值>2和年龄<2岁为死亡或移植的显著危险因素。
  • 5年和10年无二尖瓣再置换率分别为90±3%和72±6%。

关键数值与推荐

  • 首次置换置入生物瓣(P = 0.007)和尺寸/体重比值>2(P = 0.048)为再手术预测因素。
  • 再置换时观察到二尖瓣假体显著增大(P < 0.0001)。

临床怎么用

  • 对儿童二尖瓣置换可依据尺寸/体重比值和年龄<2岁评估死亡风险。
  • 再置换手术并发症和死亡率低,再手术时可考虑置入更大尺寸假体。

局限性

  • 单中心回顾性设计,样本量有限,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to identify the predictors of death and of reintervention after mitral valve replacement (MVR) in children. METHODS: A single-centre retrospective study was performed including 115 patients under the age of 18 undergoing MVR between 1982 and 2019. For all patients, the ratio of prosthetic valve size (diameter in mm) to weight (kg) at surgery was calculated and long-term result was assessed. The primary outcome was freedom from mitral valve (MV) re-replacement. The composite secondary outcome was freedom from death or transplant. RESULTS: Fifty-four patients had a previous surgical attempt to MV repair. The median age at surgery was 5.5 years (interquartile range 1.21-9.87). Death/transplant-free survival was 77 ± 4% at 5 years and 72 ± 5% at 10 years. Univariate analysis showed a size/weight ratio higher than 2 and age <2 years as significant risk factors for death or transplant. Freedom from MV re-replacement at 5 and 10 years was 90 ± 3% and 72 ± 6%, respectively. Biological prosthesis implanted at first replacement (P = 0.007) and size/weight ratio higher than 2 (P = 0.048) were predictors of reoperation. Significant upsizing (P < 0.0001) of mitral prosthesis was observed at re-replacement. CONCLUSIONS: MVR is a viable strategy in children with unrepairable MV disease. Mortality can be predicted based on size/weight ratio and age <2 years. MV re-replacement can be performed with low morbidity and mortality and a larger-size prosthesis can often be placed at the time of redo.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Brancaccio G, Trezzi M, Chinali M, et al. Predictors of survival in paediatric mitral valve replacement. Eur J Cardiothorac Surg. 2021. PMID: 33582753. doi:10.1093/ejcts/ezab078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。